Intraluminal device and therapeutic agent combination for treating aneurysmal disease

• US 20070083258A1
• Filed: 10/06/2005
• Published: 04/12/2007
• Est. Priority Date: 10/06/2005
• Status: Abandoned Application

• Current Assignee: Cordis Corporation (Cardinal Health, Inc.)
• Original Assignee: Cordis Corporation (Cardinal Health, Inc.)
• Inventors: Falotico, Robert, Narayanan, Pallassana
• Application Number:
  US11/244,903
• Publication Number:
  US 20070083258A1
• Time in Patent Office: Days
• US Class Current: 623/1.420
• CPC Class Codes: A61F 2/07 Stent-grafts
• CPC Class Codes: A61F 2/848 having means for fixation to the vessel wall, e.g. barbs
• CPC Class Codes: A61F 2/90 characterised by a net-like or mesh-like structure
• CPC Class Codes: A61F 2/915 with bands having a meander structure, adjacent bands being connected to each other
• CPC Class Codes: A61F 2002/075 the stent being loosely attached to the graft material, e.g. by stitching
• CPC Class Codes: A61F 2210/0076 multilayered, e.g. laminated structures
• CPC Class Codes: A61F 2220/0016 with sharp anchoring protrusions, e.g. barbs, pins, spikes
• CPC Class Codes: A61F 2250/0067 Means for introducing or releasing pharmaceutical products into the body
• CPC Class Codes: A61L 2300/45 Mixtures of two or more drugs, e.g. synergistic mixtures
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/08 Vasodilators for multiple indications
• CPC Class Codes: A61P 9/14 Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Abstract

Medical devices, and in particular implantable medical devices, may be coated to minimize or substantially eliminate a biological organism'"'"'s reaction to the introduction of the medical device to the organism. The medical devices may be coated with any number of biocompatible materials. Therapeutic drugs, agents or compounds may be mixed with the biocompatible materials and affixed to at least a portion of the medical device. These therapeutic drugs, agents or compounds may also further reduce a biological organism'"'"'s reaction to the introduction of the medical device to the organism. In addition, these therapeutic drugs, agents and/or compounds may be utilized to promote healing, including the formation of blood clots. The drugs, agents, and/or compounds may also be utilized to treat specific diseases, including vulnerable plaque. Therapeutic agents may also be delivered to the region of a disease site. In regional delivery, liquid formulations may be desirable to increase the efficacy and deliverability of the particular drug. Also, the devices may be modified to promote endothelialization. Various materials and coating methodologies may be utilized to maintain the drugs, agents or compounds on the medical device until delivered and positioned. In addition, the devices utilized to deliver the implantable medical devices may be modified to reduce the potential for damaging the implantable medical device during deployment. Medical devices include stents, grafts, anastomotic devices, perivascular wraps, sutures and staples. In addition, various polymer combinations may be utilized to control the elution rates of the therapeutic drugs, agents and/or compounds from the implantable medical devices.

Claims

1. A medical device comprising:

an implantable intraluminal medical device; and

a combination of at least two agents, in therapeutic dosages, releasably affixed to the implantable intraluminal medical device for the treatment of aneurysmal disease, a first of the at least two agents being released for a first sustained period of time to regulate the elastolytic activity of a matrix metalloproteinase and gelatinase and a second of the at least two agents comprising analogs, derivatives and congeners that bind a high infinity cytosolic protein, FKBP12.

2. The drug delivery device according to claim 1, wherein the first agent comprises a tetracycline compound.

3. The drug delivery device according to claim 1, wherein the intraluminal medical device comprises a stent-graft.

4. The drug delivery device according to claim 1, wherein the intraluminal medical device comprises an aneurysmal repair device.

5. The drug delivery device according to claim 3, wherein the at least two agents are incorporated in a non-erodible polymeric matrix coating affixed to the stent-graft.

6. The drug delivery device according to claim 4, wherein the at least two agents are incorporated in a non-erodible polymeric matrix coating affixed to the aneurysmal repair device.

7. An aneurysmal repair device comprising:

at least one bypass prosthesis configured to establish a fluid flow path through an aneurysmal section of an artery; and

at least two agents affixed to at least a portion of the at least one bypass prosthesis, a first of the at least two agents being released for a sustained period of time to regulate the elastolytic activity of a matrix metalloproteinase and gelatinase and a second of the at least two agents comprising analogs, derivatives and congeners that bind a high infinity cytosolic protein, FKBP12.

8. The aneurysmal repair device according to claim 7, wherein the first agent comprises a tetracycline compound.

9. The aneurysmal repair device according to claim 7, wherein the at least one-bypass prosthesis comprises a stent.

10. The aneurysmal repair device according to claim 9, wherein the at least one-bypass prosthesis further comprises a graft affixed to the stent.

11. The aneurysmal repair device according to claim 7, wherein the at least one-bypass prosthesis comprises a graft.

12. The aneurysmal repair device according to claim 7, wherein the at least two agents are incorporated in a non-erodible polymeric matrix coating affixed to the at least one-bypass prosthesis.

13. An aneurysmal repair device comprising:

at least one-bypass prosthesis configured to establish a fluid flow path through an aneurysmal section of an artery; and

a drug delivery depot operatively associated with the at least one-bypass prosthesis, the drug delivery depot configured to deliver at least two agents, a first of the at least two agents being released for a first sustained period of time to regulate the elastolytic activity of a matrix metalloproteinase and gelatinase and a second of the at least two agents comprises analogs, derivatives and congeners that bind a high infinity cytosolic protein, FKBP12.